NCT05941793View on ClinicalTrials.gov

A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

August 12, 2024

Study Completion Date

August 12, 2024

Conditions
Mild to Moderate COVID-19
Interventions
DRUG

MBS-COV

MBS-COV for inhalation

DRUG

Placebo

Placebo for inhalation

Trial Locations (5)

84088

Velocity Clinical Research, Salt Lake City

Unknown

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare, New Taipei City

National Taiwan University Hospital, Taipei

Taipei Medical University Hospital, Taipei

Taipei Municipal Wanfang Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Oneness Biotech Co., Ltd.

INDUSTRY

NCT05941793 - A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients | Biotech Hunter | Biotech Hunter